Evidence-Based Treatment Options
Promising Interim Results from Clinical Trial of NIH-Moderna COVID-19 Vaccine(11/16/20) ▸
An independent data and safety monitoring board (DSMB) overseeing the Phase 3 trial of the investigational COVID-19 vaccine known as mRNA-1273 reviewed trial data and shared its interim analysis with the trial oversight group on Nov. 15, 2020. This interim review of the data suggests that the vaccine is safe and effective at preventing symptomatic COVID-19 in adults.
Pfizer reports 90% efficacy for COVID-19 vaccine candidate (11/09/20) ▸
Pfizer Inc. announced that BNT162b2, its mRNA-based vaccine candidate, is more than 90% effective in preventing COVID-19, based on early data that has yet to be peer-reviewed.
Should Remdesivir Be Used for the Treatment of Patients With COVID-19? Rapid, Living Practice Points From the American College of Physicians (Version 1) (10/05/20) ▸
These clinical guidelines discuss an ongoing review of the effectiveness of Remdesivir treatment on COVID-19 patients with mild and severe symptoms.
Remdesivir for Adults With COVID-19 A Living Systematic Review for an American College of Physicians Practice Points (10/05/20) ▸
The American College of Physicians review the effectiveness and harms of remdisivir treatment for COVID-19.
Update Alert 4: Risks and Impact of Angiotensin-Converting Enzyme Inhibitors or Angiotensin-Receptor Blockers on SARS-CoV-2 Infection in Adults (09/22/20) ▸
Findings from 19 observational studies are overall consistent with prior evidence that found a lack of association between angiotensin-converting enzyme inhibitor (ACEI) and angiotensin-receptor blocker (ARB) use and more severe coronavirus disease 2019 (COVID-19).
Corticosteroids for COVID-19 (09/02/20) ▸
This guideline reflects an innovation from the WHO, driven by an urgent need for global collaboration to provide trustworthy and living COVID-19 guidance informing policy and practice worldwide during an outbreak of an emerging infectious disease, such as this pandemic. For this purpose, WHO has partnered with the non-profit Magic Evidence Ecosystem Foundation (MAGIC) for methodologic support, to develop and disseminate living guidance for COVID-19 drug treatments.
COVID-19 Update: FDA Broadens Emergency Use Authorization for Veklury (remdesivir) to Include All Hospitalized Patients for Treatment of COVID-19 (08/28/20) ▸
On August 28, as part of its ongoing efforts to fight COVID-19, the U.S. Food and Drug Administration broadened the scope of the existing emergency use authorization (EUA) for the drug Veklury (remdesivir) to include treatment of all hospitalized adult and pediatric patients with suspected or laboratory-confirmed COVID-19, irrespective of their severity of disease.
Considerations for Selecting Respirators for Your Health Care Facility (08/18/20) ▸
The FDA has released two flowcharts and information on respirators.
Duration of Isolation and Precautions for Adults with COVID-19 (08/16/20) ▸
At this time, we do not know if someone can be re-infected with COVID-19. Data to date show that a person who has had and recovered from COVID-19 may have low levels of virus in their bodies for up to 3 months after diagnosis. This means that if the person who has recovered from COVID-19 is retested within 3 months of initial infection, they may continue to have a positive test result, even though they are not spreading COVID-19.
Interim Guidance for Rapid Antigen Testing for SARS-CoV-2 (08/16/20) ▸
Antigen tests are relatively inexpensive and can be used at the point-of-care. The currently authorized devices return results in approximately 15 minutes. Antigen tests for SARS-CoV-2 are generally less sensitive than viral tests that detect nucleic acid using reverse transcription polymerase chain reaction (RT-PCR).
Ventilators and Ventilator Accessories EUAs (08/10/20) ▸
This EUA authorizes the emergency use of certain ventilators, anesthesia gas machines modified for use as ventilators, positive pressure breathing devices modified for use as ventilators, ventilator tubing connectors, and ventilator accessories that the FDA determines meet specified criteria for safety, performance, and labeling. The devices that are eligible for inclusion under the EUA are those that are not currently marketed in the U.S., or those that are currently marketed in the U.S. but a modification is made to the device that would trigger the requirement that a manufacturer submit a new premarket notification (510(k)) to the FDA, as discussed in the agency’s Ventilator Enforcement Policy.
LitCOVID Systematic Review Daily Report (08/06/20) ▸
This is a subset of the PubMed LitCovid curated list of articles relating to COVID-19. The articles were critically assessed by researchers, faculty, and graduate students from Spectrum Health West Michigan, Van Andel Institute, Michigan State University, Ferris State University, Simmons University, and Henry Ford Health System. They were systematically selected from 3439 papers reviewed by our volunteers based on their scientific merit, impact, or perceived importance. See the About section for details on methods and scoring.
Assessment of Evidence for COVID-19 Related Treatments (08/05/20) ▸
Evidence table to help practitioners better understand current approaches related to treatment and care.
Multiplex Assay for Flu and COVID-19 & Supplies (08/02/20) ▸
The U.S. Food and Drug Administration (FDA) granted Emergency Use Authorization (EUA) for this test on July 2, 2020. Test kits are in production and will be shipped to public health laboratories once production, including quality control and assembly, has been completed.
FDA Authorizes Propofol Emulsion for Emergency Use for COVID-19 Ventilator Sedation (document updated 7/28/20) ▸
The Food and Drug Administration May 8 authorized the emergency use of Fresenius Propoven 2% Emulsion, which the agency says “may be effective to maintain sedation via continuous infusion in patients greater than 16 years old with suspected or confirmed COVID-19 who require mechanical ventilation in an ICU setting.”
COVID 19 Testing – Guide for Physicians (07/28/20) ▸
Information on coronavirus testing options and availability is changing rapidly. Tests and specimen collection components remain in short supply and are being directed to areas of greatest need. To date, no coronvirus tests have been approved by the FDA. But tests are available under Emergency Use Authorization (EUA), which means the FDA has not thoroughly vetted these tests to grant full approval.
Evidence Used to Update the List of Underlying Medical Conditions that Increase a Person’s Risk of Severe Illness from COVID-19 (07/28/20) ▸
Updates to the list of underlying medical conditions that put individuals at increased risk for severe illness from COVID-19 were based on published reports, articles in press, unreviewed pre-prints, and internal data available between December 1, 2019 and July 10, 2020, 2020.
Duration of Isolation and Precautions for Adults with COVID-19 (07/22/20) ▸
This update incorporates recent evidence to inform the duration of isolation and precautions recommended to prevent transmission of SARS-CoV-2 to others, while limiting unnecessary prolonged isolation and unnecessary use of laboratory testing resources.
CDC Consolidates Testing Guidance (07/17/20) ▸
The Centers for Disease Control and Prevention has consolidated its recommendations for COVID-19 testing, which it will update as additional information becomes available. The agency also released testing strategy options for high-density critical infrastructure workplaces, such as law enforcement, agriculture and critical manufacturing.
Panel develops NIH treatment guidelines for COVID-19 (07/17/20) ▸
A panel of U.S. physicians, statisticians, and other experts have developed a “living document” treatment guidelines for COVID-19.
An mRNA Vaccine against SARS-CoV-2 — Preliminary Report (07/14/20) ▸
We conducted a first-in-human phase 1 clinical trial in healthy adults to evaluate the safety and immunogenicity of mRNA-1273. Here we report interim results of the trial.
Authorization of Emergency Use of Certain Medical Devices During COVID-19; Availability (07/14/20) ▸
The Food and Drug Administration (FDA) is announcing the issuance and reissuance of Emergency Use Authorizations (EUAs) (the Authorizations) for certain medical devices related to the Coronavirus Disease 2019 (COVID-19) public health emergency. FDA has issued, and in some cases reissued, the Authorizations listed in this document under the Federal Food, Drug, and Cosmetic Act (FD&C Act). These Authorizations contain, among other things, conditions on the emergency use of the authorized products.
FDA Cautions Against Use of Hydroxychloroquine or Chloroquine for COVID-19 Outside of the Hospital Setting or a Clinical Trial Due to Risk of Heart Rhythm Problems (07/01/20)▸
Based on ongoing analysis and emerging scientific data, FDA has revoked the emergency use authorization (EUA) to use hydroxychloroquine and chloroquine to treat COVID-19 in certain hospitalized patients when a clinical trial is unavailable or participation is not feasible. For more information please visit the following link: Frequently Asked Questions on the Revocation of the Emergency Use Authorization for Hydroxychloroquine Sulfate and Chloroquine Phosphate.
Low-Cost Dexamethasone Reduces Death by up to One Third in Hospitalised Patients with Severe Respiratory Complications of COVID-19 (06/16/20) ▸
In March 2020, the RECOVERY (Randomised Evaluation of COVid-19 thERapY) trial was established as a randomised clinical trial to test a range of potential treatments for COVID-19, including low-dose dexamethasone (a steroid treatment). Over 11,500 patients have been enrolled from over 175 NHS hospitals in the UK.
Medical Operations Coordination Cells Toolkit (05/13/20) ▸
Learn to establish Medical Operations Coordination Cells (MOCCs) to ensure load-balancing across health care facilities and systems.
Innovation Transforms Bi-level Positive Airway Pressure Machines into Ventilators (03/31/20) ▸
New York’s Northwell Health develops protocol to turn bi-level positive airway pressure (BiPAP) machine into a functional invasive mechanical ventilator.
Ventilator Sharing Protocol (03/26/20) ▸
Dual-patient ventilation with a single mechanical ventilator for use during critical ventilator shortages.